Thousands of investors use this no cost solution | Do you?

In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

Thomas Garrity Biography and Net Worth

Director of Antares Pharma

Mr. Garrity joined the Board of Directors in October 2003 and serves as Chairman of our Audit Committee and as a member of our Governance and Nominating Committee. He was Executive Vice President and Chief Financial Officer for PCS Health Systems, a provider of managed pharmaceutical care, from 1994 to 2000. He played a key role during its subsequent integration with Advance Paradigm, Inc. and became Executive Vice President of Financial Operations for the resultant entity, Advance PCS, a provider of health improvement solutions. Prior to that, Mr. Garrity held various positions at Eli Lilly and Company, including Director of Public Policy Planning and Development; Director of Corporate Financial Planning; and other international, marketing and financial positions. Mr. Garrity holds a B.S. degree from the Massachusetts Institute of Technology in aerospace engineering and an MBA in finance from the University of Chicago. He is currently a private investor and consultant.

Mr. Garrity's long executive experience in the pharmaceutical arena and additional extensive experience in leadership positions in pharmaceutical companies enable him to assist the Board of Directors in assessing government regulatory considerations and other matters facing the pharmaceutical industry and the companies operating therein. In addition, his experience as a financial executive enables him to provide knowledgeable perspectives on financial matters.

What is Thomas J. Garrity's net worth?: The estimated net worth of Thomas J. Garrity is at least $1.53 million as of March 11th, 2021. Mr. Garrity owns 274,406 shares of Antares Pharma stock worth more than $1,533,930 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Garrity may own. Learn More about Thomas J. Garrity's net worth.
How do I contact Thomas J. Garrity?: The corporate mailing address for Mr. Garrity and other Antares Pharma executives is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. Antares Pharma can also be reached via phone at (609) 359-3020 and via email at [email protected]. Learn More on Thomas J. Garrity's contact information.
Has Thomas J. Garrity been buying or selling shares of Antares Pharma?: Thomas J. Garrity has not been actively trading shares of Antares Pharma in the last ninety days. Most recently, Thomas J. Garrity sold 50,000 shares of the business's stock in a transaction on Thursday, March 11th. The shares were sold at an average price of $4.28, for a transaction totalling $214,000.00. Following the completion of the sale, the director now directly owns 274,406 shares of the company's stock, valued at $1,174,457.68. Learn More on Thomas J. Garrity's trading history.
Who are Antares Pharma's active insiders?: Antares Pharma's insider roster includes Thomas Garrity (Director), and Anton Gueth (Director). Learn More on Antares Pharma's active insiders.

Thomas J. Garrity Insider Trading History at Antares Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2021	Sell	50,000	$4.28	$214,000.00	274,406
2/11/2021	Sell	50,000	$4.62	$231,000.00	274,406
1/11/2021	Sell	70,000	$4.06	$284,200.00	244,406
12/9/2019	Sell	80,000	$4.58	$366,400.00	234,186
5/1/2019	Sell	30,000	$2.67	$80,100.00	190,213
10/3/2017	Sell	30,000	$3.50	$105,000.00
3/31/2017	Sell	30,000	$2.91	$87,300.00	190,213
5/31/2013	Sell	13,000	$4.08	$53,040.00

Thomas J. Garrity Buying and Selling Activity at Antares Pharma

Antares Pharma Company Overview

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

Today's Range

Now: $5.59

$5.59

50 Day Range

MA: $5.59

$5.59

2 Week Range

Now: $5.59

$3.11

$5.60

Volume

6 shs

Average Volume

3,291,313 shs

Market Capitalization

$955.06 million

P/E Ratio

23.29

Dividend Yield

N/A

Beta

1.15